BFB759
Phase 2Biologic
BFB759 is one of 74 biologic programs targeting Atopic Dermatitis. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
73
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
508 competitors in Atopic Dermatitis
#DrugCompanyPhaseTrials
1Nereus
VVanda Pharmaceuticals
Phase 3
Celestone
SSchering-Plough
Phase 3
Tagamet
DDT MedTech, LLC
Phase 3
Bepreve
BBausch Health Americas, Inc.
Phase 3
GR1802
GGenrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 3
EBGLYSS
Eli LillyPreclinical
Cibinqo
PfizerPreclinical
OPA-15406
OtsukaPhase 3
Prograf
VVeloxis Pharmaceuticals
Preclinical
IDP-124 Lotion
BBausch Health Americas, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for BFB759. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- BBluefin Biomedicine, Inc.